Simlandi Kit
Product Images NDC 50090-7718

Product Visual Gallery

This gallery contains 49 technical images submitted to the FDA as part of the official labeling for Simlandi (NDC 50090-7718). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

A line graph showing the percentage of AC R20 responders over time in weeks, comparing two groups: one receiving 40 mg every other week and a placebo group. The graph displays increasing response percentages for the treatment group relative to the placebo over the course of 48 weeks.*

FDA Label Image

10 (Image 10)

An instructional illustration labeled Figure E showing hands being washed under running water from a faucet, emphasizing proper hygiene or preparation steps prior to use.*

FDA Label Image

11 (Image 11)

An illustration labeled 'Figure F' shows a front view of a human torso and upper legs with highlighted orange areas indicating recommended subcutaneous injection sites on the abdomen and upper thighs.*

FDA Label Image

12 (Image 12)

An instructional illustration labeled Figure G shows a hand using a circular motion with a cotton pad or swab on a surface, indicating a cleaning or wiping action.*

FDA Label Image

13 (Image 13)

An illustration of the Simlandi (adalimumab-ryvk) injection pen showing a close-up view of the dose window filled with liquid. The image highlights the 40 mg/0.4 mL subcutaneous injection pen, labeled with the proprietary name Simlandi and the manufacturer Teva, depicting the internal fill level indicator.*

FDA Label Image

14 (Image 14)

An instructional illustration showing a hand holding a prefilled subcutaneous injection pen labeled '40 mg/0.4 mL' and 'teva.' The pen is shown with an orange cap being removed by the thumb and index finger of another hand, indicating the first step in preparing the injection device for use.*

FDA Label Image

15 (Image 15)

An instructional illustration showing a hand holding a Simlandi (adalimumab-ryvk) prefilled pen or injector at a 90-degree angle to the skin on the opposite hand, demonstrating the proper technique for subcutaneous injection.*

FDA Label Image

16 (Image 16)

Illustration showing two steps for administering a subcutaneous injection with a pen device containing 40 mg/0.4 mL. Figure K depicts the first click as the device is pressed against the skin, and Figure L shows the second click after waiting up to 10 seconds, indicating completion of the injection.*

FDA Label Image

17 (Image 17)

An instructional diagram showing a hand holding a Simlandi (adalimumab-ryvk) pen injector and an arrow pointing upward, indicating the direction for injection. Below, a second image shows the hand pressing the pen injector against the skin, labeled Figure M, illustrating subcutaneous administration technique.*

FDA Label Image

18 (Image 18)

An illustration showing a hand disposing of a used single-dose pen or injector into a red sharps container with a yellow lid. The pen is labeled with a partially visible brand name and marked as used. This diagram likely demonstrates safe disposal instructions for medical sharps.*

FDA Label Image

19 (Image 19)

FDA Label Image

2 (Image 2)

A line graph depicting the percentage of ASAS 20 response over 24 weeks for Adalimumab and placebo groups. The x-axis represents time in weeks, while the y-axis shows the percentage response. The Adalimumab group (N=208) shows a higher and sustained response rate compared to the placebo group (N=107) throughout the period.*

FDA Label Image

Parts (Image 20)

An instructional illustration of a subcutaneous injection device showing labeled parts including the clear cap, needle, orange needle sleeve, inspection window, and gray body grip area. The diagram visually details the components and layout of the injection tool typically used in self-administration kits.*

FDA Label Image

A (Image 21)

An instructional diagram labeled Figure A shows a hand inserting a rectangular object into a slot on a device. The image likely illustrates a step in using or assembling the product associated with Simlandi, adalimumab-ryvk, a subcutaneous kit by A-S Medication Solutions.*

FDA Label Image

B (Image 22)

Illustration of a clock face indicating a time period of 15 to 30 minutes, highlighted by a red shaded area covering the right half of the clock, labeled as Figure B.*

FDA Label Image

C (Image 23)

An illustration of the Simlandi adalimumab-ryvk subcutaneous injection kit components. The image shows a vial with a label area indicating where to record the lot number and expiration date, and a connected injection device with a handle and a perforated surface section, labeled as Figure C.*

FDA Label Image

D (Image 24)

An instructional diagram labeled Figure D showing a self-injection pen device with components including an alcohol swab packet, a cotton ball, and a red biohazard disposal container. The image is likely part of insertion or injection instructions for the Simlandi adalimumab-ryvk kit.*

FDA Label Image

D (Image 25)

Illustration showing a person's hands holding a small object under running water from a faucet, labeled as Figure E. This image appears to demonstrate a cleaning or washing step, possibly related to medication preparation or device use.*

FDA Label Image

F (Image 26)

An anatomical illustration labeled 'Figure F' showing a human torso with highlighted areas in orange on the abdomen and the front of both thighs, indicating preferred sites for subcutaneous injection.*

FDA Label Image

G (Image 27)

This instructional diagram labeled 'Figure G' depicts a hand pressing a white object, possibly a patch or pad, onto the skin with circular arrows indicating a rotating motion for application or removal.*

FDA Label Image

H (Image 28)

An instructional diagram showing a Simlandi adalimumab-ryvk subcutaneous injection kit component with a close-up detail of the fluid window area, indicating liquid presence inside the device. The diagram is labeled as Figure H.*

FDA Label Image

I (Image 29)

Illustration showing a hand holding a Simlandi injection device, with an arrow pointing downward toward a small adhesive patch held by another hand, demonstrating removal or application of the patch following use of the subcutaneous injection kit.*

FDA Label Image

3 (Image 3)

A line graph depicting treatment failure rate (%) over time (months) comparing treatment groups: placebo and adalimumab. The x-axis represents time in months up to 20, and the y-axis shows treatment failure rate percentage from 0 to 100%. The graph includes numerical data points and distinguishes the treatment and placebo groups with separate lines.*

FDA Label Image

J (Image 30)

An instructional illustration showing how to hold and inject a Simlandi (adalimumab-ryvk) subcutaneous injection kit at a 90-degree angle into the skin on a person's arm. The diagram emphasizes proper injection angle and hand positioning.*

FDA Label Image

Kl (Image 31)

An instructional illustration showing two steps for using a subcutaneous injection device from the Simlandi adalimumab-ryvk kit. Figure K depicts the injection with the first click, and a clock icon indicates to wait up to 15 seconds. Figure L shows the second click, indicating completion of the injection.*

FDA Label Image

M (Image 32)

Illustration showing a hand holding an injection device vertically with an upward arrow indicating the injection direction, paired with a depiction of an arm being prepared for subcutaneous injection below, labeled as Figure M. This illustration is likely part of instructions for using the Simlandi (adalimumab-ryvk) subcutaneous injection kit.*

FDA Label Image

N (Image 33)

An instructional illustration labeled 'Figure N' showing a hand disposing of a used injectable pen into a red sharps disposal container with a yellow lid, demonstrating safe disposal of injection device components.*

FDA Label Image

19 (Image 34)

FDA Label Image

Parts1 (Image 35)

Illustration showing a labeled syringe with parts identified as Needle Cover, Syringe Body, Finger Grip, and Plunger. The diagram highlights the components of a syringe intended for subcutaneous administration.*

FDA Label Image

Apfs1 (Image 36)

An instructional illustration showing a hand holding a kit box with an arrow indicating it should be placed inside a refrigerator. The image emphasizes proper storage of the medication kit in a refrigerated environment.*

FDA Label Image

Bpfs1 (Image 37)

An illustration of a clock with a red highlight covering the 15 to 30 minute segment. The text '15 to 30 minutes' is displayed inside the clock face, indicating a time interval.*

FDA Label Image

Cpfs1 (Image 38)

Illustration showing the use of a Simlandi (adalimumab-ryvk) subcutaneous injection kit. It depicts a hand holding the prefilled injector with an arrow pointing to the viewing window for checking the medication inside, alongside an inset showing injection site on the upper arm near the shoulder.*

FDA Label Image

Dpfs1 (Image 39)

Illustration showing three items typically used in medical procedures: a sealed alcohol swab packet, a small cotton ball, and a red sharps disposal container with a yellow lid and an oval opening.*

FDA Label Image

4 (Image 4)

A line graph comparing treatment failure rates (%) over time (months) between placebo and adalimumab groups. The x-axis shows time in months with corresponding sample sizes, and the y-axis shows treatment failure rate percentage, illustrating lower failure rates for adalimumab compared to placebo.*

FDA Label Image

Epfs1 (Image 40)

An instructional illustration showing hands being washed under a running faucet. Water flows over soapy hands, demonstrating proper handwashing technique to ensure cleanliness before handling medication.*

FDA Label Image

Fpfs1 (Image 41)

An instructional illustration showing preferred injection sites for a subcutaneous administration kit. The highlighted areas include the abdomen around the navel and the front of both thighs. Inset shows a hand peeling back adhesive backing, indicating preparation of the injection site or device.*

FDA Label Image

Gpfs1 (Image 42)

An instructional diagram showing hands preparing a syringe and removing a protective cap by pulling it upward away from the needle. The illustration demonstrates a step in the preparation for subcutaneous injection, likely related to the Simlandi adalimumab-ryvk kit.*

FDA Label Image

Hpfs1 (Image 43)

An instructional illustration showing a hand holding a syringe and preparing to administer a subcutaneous injection into the skin of another person's arm, with one hand pinching the skin to create a suitable injection site.*

FDA Label Image

Ipfs1 (Image 44)

An instructional illustration showing two subcutaneous injection sites for Simlandi (adalimumab-ryvk) kit. One image demonstrates a 45-degree injection angle into the abdomen, and the other shows a 45-degree injection angle into the thigh. Both images highlight proper needle insertion technique for self-administration.*

FDA Label Image

Jpfs1 (Image 45)

An instructional illustration showing a hand holding a syringe injecting a subcutaneous dose into the skin. The syringe appears to be part of a kit, likely for the administration of Simlandi (adalimumab-ryvk). The image includes an arrow pointing to the injection site on the skin.*

FDA Label Image

Kpfs1 (Image 46)

An instructional illustration showing the use of a subcutaneous injection kit. The image depicts a hand pressing a cotton ball on the injection site while the other hand is removing the cap from the prefilled injector pen, likely Simlandi (adalimumab-ryvk) kit, before administering the injection.*

FDA Label Image

Lpfs1 (Image 47)

An instructional illustration showing a hand disposing of a syringe into a red sharps container through a yellow lid opening. The image demonstrates safe syringe disposal procedure, relevant for subcutaneous medication use such as Simlandi (adalimumab-ryvk) kit.*

FDA Label Image

Calpfs1 (Image 48)

An illustration of a monthly calendar with a grid of circular date markers. Some markers are filled in white and others in gray, indicating a tracking or scheduling aid, commonly used for medication adherence or dose tracking.*

FDA Label Image

5 (Image 5)

An instructional diagram of a Simlandi (adalimumab-ryvk) subcutaneous administration kit. The image labels components including a clear cap, needle, orange needle sleeve, inspection window with dosage markings, and a gray body grip area with a honeycomb texture pattern.*

FDA Label Image

6 (Image 6)

An instructional diagram labeled Figure A showing a hand holding a rectangular box, positioned to be inserted into an open refrigerator door compartment.*

FDA Label Image

7 (Image 7)

An illustration of a clock face showing a 15 to 30 minute time interval highlighted in red. The text "15 to 30 minutes" appears inside the clock circle, with the clock face marked at 12, 3, 6, and 9 o'clock positions. Below the illustration, the label "Figure B" is present.*

FDA Label Image

8 (Image 8)

Illustration of the Simlandi (adalimumab-ryvk) subcutaneous injection kit components, showing the assembled device with label displaying drug name and volume (40 mg/0.4 mL). Also includes a callout for expiration date (EXP: YYYY/MM/DD) and lot number location on the packaging.*

FDA Label Image

9 (Image 9)

An instructional diagram labeled Figure D shows components of the Simlandi adalimumab-ryvk subcutaneous injection kit. The illustration includes a prefilled auto-injector pen labeled with the drug name and strength, an alcohol swab packet, a cotton ball, and a red sharps disposal container with a yellow lid.*

FDA Label Image

Label Image (Lbl500907718)

Label for Simlandi 40 mg/0.4 mL subcutaneous injection kit by A-S Medication Solutions. The label shows the NDC 50090-7718-0 and specifies storage at 36 to 46 degrees Fahrenheit. The package quantity is 24 kits per case, distributed by A-S Medication Solutions in Libertyville, Illinois.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.